Lexaria Bioscience (LEXX) Operating Margin (2017 - 2026)

Lexaria Bioscience has disclosed Operating Margin across 10 years of filings, most recently posting 7259.52% for Q1 2026.

• Operating Margin for Q1 2026 came in at 7259.52%, down 567847.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 2571.89% (down 78689.0% YoY), and the FY2025 annual result was 1683.01%, down 44385.0% from the prior year.
• Operating Margin came in at 7259.52% for Q1 2026 at Lexaria Bioscience, down from 1545.17% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 460.69% in Q1 2024 to a low of 7259.52% in Q1 2026.
• The 5-year median for Operating Margin is 2115.16% (2024), against an average of 2665.38%.
• Across the five-year window, Operating Margin jumped 1269960 bps in 2022 and slumped 567847 bps in 2026, its largest moves.
• Lexaria Bioscience's Operating Margin stood at 1734.71% in 2022, then soared by 57 bps to 753.01% in 2023, then sank by 94 bps to 1462.95% in 2024, then fell by 6 bps to 1545.17% in 2025, then plunged by 370 bps to 7259.52% in 2026.
• The last three Operating Margin figures came in at 7259.52% (Q1 2026), 1545.17% (Q3 2025), and 2155.41% (Q2 2025), per Business Quant data.